35. 天疱瘡 Pemphigus Clinical trials / Disease details
臨床試験数 : 98 / 薬物数 : 126 - (DrugBank : 41) / 標的遺伝子数 : 23 - 標的パスウェイ数 : 168
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2018-002146-37-IT (EUCTR) | 20/03/2019 | 04/11/2020 | A study to test if increasing doses of the drug INCB050465 is safe and well tolerated in patients with Pemphigus Vulgaris | A Phase 2 Dose-Escalation Study of the Safety and Tolerability of INCB050465 in Participants With Pemphigus Vulgaris - NA | Pemphigus vulgaris MedDRA version: 20.0;Level: LLT;Classification code 10052802;Term: Pemphigus vulgaris;System Organ Class: 100000004858;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Trade Name: NA Product Name: INCB050465 1.0 mg Product Code: [NA] INN or Proposed INN: INCB050465 Product Name: INCB050465 0.3 mg Product Code: [NA] INN or Proposed INN: INCB050465 Product Name: INCB050465 2.5mg Product Code: [NA] INN or Proposed INN: INCB050465 HYDROCHLORIDE | INCYTE CORPORATION | NULL | Not Recruiting | Female: yes Male: yes | 18 | Phase 2 | France;Canada;Italy | ||
| 2 | NCT03780166 (ClinicalTrials.gov) | March 2019 | 17/12/2018 | A Study of the Safety and Tolerability of INCB050465 in Pemphigus Vulgaris | A Phase 2 Dose-Escalation Study of the Safety and Tolerability of INCB050465 in Participants With Pemphigus Vulgaris | Pemphigus Vulgaris | Drug: Parsaclisib | Incyte Corporation | NULL | Withdrawn | 18 Years | 80 Years | All | 0 | Phase 2 | NULL |
| 3 | EUCTR2018-002146-37-FR (EUCTR) | 24/01/2019 | 01/10/2018 | A study to test if increasing doses of the drug INCB050465 is safe and well tolerated in patients with Pemphigus Vulgaris | A Phase 2 Dose-Escalation Study of the Safety and Tolerability of INCB050465 in Participants With Pemphigus Vulgaris | Pemphigus vulgaris MedDRA version: 20.0;Level: LLT;Classification code 10052802;Term: Pemphigus vulgaris;System Organ Class: 100000004858 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: INCB050465 0.3mg INN or Proposed INN: not yet assigned Other descriptive name: INCB050465 HYDROCHLORIDE Product Name: INCB050465 1.0mg INN or Proposed INN: not yet assigned Other descriptive name: INCB050465 HYDROCHLORIDE Product Name: INCB050465 2.5mg INN or Proposed INN: not yet assigned Other descriptive name: INCB050465 HYDROCHLORIDE | Incyte Corporation | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 18 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | France;Canada;Italy |